Press Releases

Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013 | 2012
DateTitle 
11/20/17Alkermes Named a Top Place to Work by The Boston GlobePrinter Friendly Version
11/16/17Alkermes’ New Drug Application for Investigational Product Designed for Initiation Onto ARISTADA® Accepted for Filing by U.S. FDAPrinter Friendly Version
11/14/17VIVITROL® and Value of Medication-Assisted Treatment for Opioid Dependence Featured in Study Sponsored by National Institute on Drug AbusePrinter Friendly Version
11/09/17Alkermes Calls for Impartial National Review of Scientific Data Supporting the Use of FDA-Approved Treatment Options for Opioid DependencePrinter Friendly Version
11/09/17Alkermes Reveals Recipients of the 2nd Annual Competitive Grants Program to Support Those Affected by Mental Health and Substance Use DisordersPrinter Friendly Version
11/08/17Alkermes’ Corporate Presentation to be Webcast at the Jefferies 2017 London Healthcare ConferencePrinter Friendly Version
11/08/17Alkermes Letter to Senator HarrisPrinter Friendly Version
11/08/17Positive Preclinical Data for ALKS 4230 Presented at Society for Immunotherapy of Cancer (SITC) 32nd Annual MeetingPrinter Friendly Version
11/06/17Alkermes Responds to Senator’s InquiryPrinter Friendly Version
10/31/17Alkermes’ Corporate Presentation to be Webcast at the Credit Suisse 26th Annual Healthcare ConferencePrinter Friendly Version
10/27/17Alkermes Presents Data Demonstrating Safety and Gastrointestinal Tolerability Profile of ALKS 8700 for the Treatment of Multiple SclerosisPrinter Friendly Version
10/26/17Corporate Statement on White House Declaration to Combat Opioid EpidemicPrinter Friendly Version
10/26/17Alkermes to Initiate New Clinical Study Evaluating ARISTADA® and INVEGA SUSTENNA® for the Treatment of SchizophreniaPrinter Friendly Version
10/26/17Alkermes Unveils Investigational Product Designed for Initiation Onto ARISTADA® for Treatment of SchizophreniaPrinter Friendly Version
10/26/17Alkermes plc Reports Third Quarter 2017 Financial ResultsPrinter Friendly Version
10/19/17Alkermes to Host Conference Call to Discuss Third Quarter 2017 Financial ResultsPrinter Friendly Version
10/18/17New Study Comparing Effectiveness of Extended-Release Naltrexone to Buprenorphine-Naloxone for Opioid Dependence Published in JAMA PsychiatryPrinter Friendly Version
10/16/17Alkermes to Present New Clinical Data on ALKS 8700 at MSParis2017, the 7th Joint ECTRIMS-ACTRIMS MeetingPrinter Friendly Version
09/28/17Alkermes Participates in President’s Commission Meeting on Combating Drug Addiction and the Opioid CrisisPrinter Friendly Version
09/28/17Corporate Statement on Alkermes Testimony at Opioid Commission Meeting at White HousePrinter Friendly Version
09/18/17Patients Switched to Alkermes’ ARISTADA® Showed Significant Improvement in Schizophrenia Symptoms After Inadequate Response or Intolerance to INVEGA SUSTENNA®Printer Friendly Version
09/06/17Alkermes Announces 2nd Annual Competitive Grants Program to Support Those Affected by Mental Health and Substance Use DisordersPrinter Friendly Version
09/05/17Alkermes to Present at the Morgan Stanley 15th Annual Global Healthcare ConferencePrinter Friendly Version
09/05/17Alkermes to Present Clinical and Real-World Data at Upcoming 30th Annual Psych CongressPrinter Friendly Version
08/21/17Alkermes Initiates Rolling Submission of ALKS 5461 New Drug Application for Major Depressive DisorderPrinter Friendly Version
08/03/17Corporate Response to Recent Media Articles About Alkermes and VIVITROL®Printer Friendly Version
07/27/17Alkermes plc Reports Second Quarter 2017 Financial ResultsPrinter Friendly Version
07/20/17Alkermes to Host Conference Call to Discuss Second Quarter 2017 Financial ResultsPrinter Friendly Version
06/29/17Alkermes Announces Positive Preliminary Topline Results From Phase 3 Antipsychotic Efficacy Study of ALKS 3831 for Treatment of SchizophreniaPrinter Friendly Version
06/12/17Alkermes Announces Initiation of Study 217 for ALKS 5461 for Treatment of Major Depressive DisorderPrinter Friendly Version
06/08/17Alkermes to Present at Goldman Sachs 38th Annual Global Healthcare ConferencePrinter Friendly Version
06/08/17Alkermes Announces Initiation of Phase 3 Study of ALKS 3831 in Young Adult PatientsPrinter Friendly Version
06/06/17FDA Approves Two-Month ARISTADA® for Treatment of SchizophreniaPrinter Friendly Version
05/30/17Alkermes’ Corporate Presentation to Be Webcast at the Jefferies Healthcare ConferencePrinter Friendly Version
05/30/17Alkermes Appoints Craig Hopkinson, M.D., as Chief Medical Officer, and Senior Vice President, Clinical Development and Medical AffairsPrinter Friendly Version
05/11/17Alkermes to Present Data on ALKS 5461 at Upcoming Society of Biological Psychiatry Annual MeetingPrinter Friendly Version
05/01/17Alkermes Announces Completion of Patient Enrollment in Pivotal Antipsychotic Efficacy Study of ALKS 3831 for SchizophreniaPrinter Friendly Version
04/27/17Alkermes plc Reports First Quarter 2017 Financial ResultsPrinter Friendly Version
04/26/17Alkermes’ Corporate Presentation to be Webcast at the Deutsche Bank 42nd Annual Health Care ConferencePrinter Friendly Version
04/20/17Alkermes to Host Conference Call to Discuss First Quarter 2017 Financial ResultsPrinter Friendly Version
03/27/17Alkermes to Present Preclinical Data on ALKS 4230 at the American Association for Cancer Research Annual MeetingPrinter Friendly Version
03/20/17Alkermes to Present Data on Two-Month Dosing Option Of ARISTADA® at 16th International Congress on Schizophrenia ResearchPrinter Friendly Version
03/16/17Alkermes Initiates Phase 3 Gastrointestinal Tolerability Study of ALKS 8700 for Treatment of Multiple SclerosisPrinter Friendly Version
03/07/17Alkermes’ Corporate Presentation to be Webcast at the Barclays Global Healthcare ConferencePrinter Friendly Version
02/28/17Alkermes’ Corporate Presentation to be Webcast at the Cowen and Company 37th Annual Health Care ConferencePrinter Friendly Version
02/15/17Alkermes plc Reports Financial Results for the Year Ended Dec. 31, 2016 and Provides Financial Expectations for 2017Printer Friendly Version
02/08/17Alkermes to Host Conference Call to Discuss Fourth Quarter and Year-End 2016 Financial Results Printer Friendly Version
01/03/17Alkermes’ Corporate Presentation to be Webcast at the 35th Annual J.P. Morgan Healthcare ConferencePrinter Friendly Version

Other Resources

Email Alerts

Stay in Touch with Alkermes